In conclusion, both in vitro and in vivo studies strongly suggest that JBI-097 acts via the simultaneous inhibition of the LSD1 and HDAC6 pathways, to inhibit proliferation, enhance differentiation, and consequent tumor inhibition. Here, KDM1A is linked to neoplasm.